This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Picozzi VJ , Ramanathan RK , Lowery MA , Ocean AJ , Mitchel EP , O'Neil BH , Guarino MJ , Conkling PR , Cohen SJ , Bahary N , Frank RC , Dragovich T , Bridges BB , Braiteh FS , Starodub AN , Lee FC , Gribbin TE , Richards DA , Lee M , Korn RL , Pandit-Taskar N , Goldsmith SJ , Intenzo CM , Sheikh A , Manzone TC , Horne H , Sharkey RM , Wegener WA , O'Reilly EM , Goldenberg DM , Von Hoff DD
Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
Eur J Cancer. 2015 Sep;51(14) :1857-64
PMID: 26187510 URL: http://www.ncbi.nlm.nih.gov/pubmed/26187510
AbstractBACKGROUND: For patients with metastatic pancreatic adenocarcinoma, there are no approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated radioimmunotherapy was undertaken in this setting, administering 90Y-clivatuzumab tetraxetan (yttrium-90-radiolabelled humanised antibody targeting pancreatic adenocarcinoma mucin) with or without low radiosensitising doses of gemcitabine. METHODS: Fifty-eight patients with three (2-7) median prior treatments were treated on Arm A (N=29, 90Y-clivatuzumab tetraxetan, weekly 6.5mCi/m2dosesx3, plus gemcitabine, weekly 200mg/m2 dosesx4 starting 1week earlier) or Arm B (N=29, 90Y-clivatuzumab tetraxetan alone, weekly 6.5mCi/m2dosesx3), repeating cycles after 4-week delays. Safety was the primary endpoint; efficacy was also evaluated. RESULTS: Cytopaenias (predominantly transient thrombocytopenia) were the only significant toxicities. Fifty-three patients (27 Arm A, 26 Arm B, 91% overall) completed 1 full treatment cycles, with 23 (12 Arm A, 11 Arm B; 40%) receiving multiple cycles, including seven (6 Arm A, 1 Arm B; 12%) given 3-9 cycles. Two patients in Arm A had partial responses by RECIST criteria. Kaplan-Meier overall survival (OS) appeared improved in Arm A versus B (hazard ratio [HR] 0.55, 95% CI: 0.29-0.86; P=0.017, log-rank) and the median OS for Arm A versus Arm B increased to 7.9 versus 3.4months with multiple cycles (HR 0.32, P=0.004), including three patients in Arm A surviving >1year. CONCLUSIONS: Clinical studies of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine appear feasible in metastatic pancreatic cancer patients beyond 2nd line and a Phase III trial of this combination is now underway in this setting.
NotesPicozzi, Vincent J Ramanathan, Ramesh K Lowery, Maeve A Ocean, Allyson J Mitchel, Edith P O'Neil, Bert H Guarino, Michael J Conkling, Paul R Cohen, Steven J Bahary, Nathan Frank, Richard C Dragovich, Tomislav Bridges, Benjamin B Braiteh, Fadi S Starodub, Alexander N Lee, Fa-Chyi Gribbin, Thomas E Richards, Donald A Lee, Marie Korn, Ronald L Pandit-Taskar, Neeta Goldsmith, Stanley J Intenzo, Charles M Sheikh, Arif Manzone, Timothy C Horne, Heather Sharkey, Robert M Wegener, William A O'Reilly, Eileen M Goldenberg, David M Von Hoff, Daniel D P30 CA008748/CA/NCI NIH HHS/ Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.